GBI

Established in Shanghai in 2002 by Matthew Chervenak, GBI Health operates as a specialized provider of market intelligence for the life sciences industry. The firm primarily serves pharmaceutical and medical device companies, along with other service providers, focusing its expertise on the markets in China and Latin America. GBI's business model is centered on delivering value-added industry information, news, and data services through a portfolio of proprietary platforms and customized consulting. Revenue is generated via subscription-based access to its intelligence tools and through fees for its bespoke business intelligence services. A significant milestone in the company's history was its acquisition by Baidu on February 14, 2023, a deal facilitated by Haoyue Capital.

The company's product suite addresses various needs within the healthcare intelligence space. 'GBI SOURCE' is a global pharmaceutical database covering the entire product lifecycle, offering insights into the competitive landscape through news, policy analysis, and data tools. For tracking key opinion leaders (KOLs), 'GBI METRIX' provides a database of over one million medical researchers, integrating information from academic publications, clinical trials, and grants to map academic networks. The 'GBI DEVINT' platform is a business intelligence solution for the medtech industry in China, allowing users to track product pipelines, registrations, and tender data for medical devices and diagnostics. Additionally, 'GBI MediListen' functions as a social listening platform that uses AI to deliver real-world insights for marketing strategies, while 'GBI BI SERVICE' offers customized consulting that integrates data resources with expert analysis.

GBI's services are designed to support critical decision-making and enhance communication for its clients, which include over 95% of multinational pharmaceutical companies operating in its target regions. The firm provides comprehensive data spanning drug patents, clinical trials, pricing, and sales data for both hospital and retail channels. For the Latin American market, GBI offers analysis on regulatory changes, R&D breakthroughs, and market-specific trends, accessible through email updates or a mobile app. By offering end-to-end customized solutions, GBI assists clients in analyzing market landscapes, understanding patient behavior, and monitoring public opinion to build brand image and identify potential risks.

Keywords: market intelligence, life sciences, pharmaceutical data, medtech intelligence, China healthcare market, Latin America pharma, competitive intelligence, KOL database, drug lifecycle management, regulatory analysis, GBI SOURCE, GBI METRIX, GBI DEVINT, healthcare data services, pharmaceutical news, medical device market, Baidu acquisition, Matthew Chervenak, business intelligence tools, social listening pharma